Search | Clinical Trials Finder

Conditions: Ovarian Neoplasms
Interventions: Sorafenib (Nexavar, BAY43-9006), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 246 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 4
States / cities: La Jolla, California • Jacksonville, Florida • Augusta, Georgia + 1 more

Conditions: Defect of Articular Cartilage
Interventions: Hyalofast, Microfracture; Device · Procedure
Lead sponsor: Anika Therapeutics, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2026
U.S. locations: 18
States / cities: Tempe, Arizona • Los Angeles, California • San Diego, California + 14 more

Conditions: HIV
Interventions: Prevention & Testing, Prevention & Testing Control; Behavioral
Lead sponsor: Johns Hopkins Bloomberg School of Public Health; Other
Eligibility: 18 Years and older
Enrollment: 632 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Premature Birth, Neurodevelopmental Disorders, Brain Development Abnormality, Brain Lesion
Interventions: MRI, Neurodevelopmental/Neuropsychological Assessment; Diagnostic Test
Lead sponsor: Children's Hospital Los Angeles; Other
Eligibility: Up to 8 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Training of Mental Health Professionals, Disruptive Behavior Disorders
Interventions: Training Models of PCIT, Parent-Child Interaction Therapy (PCIT) Treatment; Behavioral
Lead sponsor: West Virginia University; Other
Eligibility: 1 Year and older
Enrollment: 648 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Posttraumatic Stress Disorder
Interventions: Clinician-Supported PTSD Coach, Primary Care Mental Health Integrated Care as Usual; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 234 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 2
States / cities: Palo Alto, California • Syracuse, New York

Conditions: Metopic Craniosynostosis
Interventions: Allogenix Plus; Biological
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 18 Months to 36 Months
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Colon Polyps
Interventions: Clip closure; Procedure
Lead sponsor: White River Junction Veterans Affairs Medical Center; Federal
Eligibility: 18 Years to 89 Years
Enrollment: 928 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 1
States / cities: White River Junction, Vermont

Conditions: Renal Impairment
Interventions: GBT440; Drug
Lead sponsor: Global Blood Therapeutics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Miami, Florida • Orlando, Florida

Conditions: Anemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions: Cyclophosphamide, Fludarabine Phosphate, Ibrutinib, Laboratory Biomarker Analysis, Pharmacogenomic Study, Quality-of-Life Assessment, Rituximab; Drug · Other · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 529 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2026
U.S. locations: 781
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 509 more

Conditions: Pregnancy Related, Thyroid
Interventions: levothyroxine; Drug
Lead sponsor: Medstar Health Research Institute; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2018
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Coronary Artery Disease, Asthma, Chronic Obstructive Pulmonary Disease (COPD), Angina
Interventions: Regadenoson, Dobutamine; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 40 Years to 85 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Allergic Rhinitis
Interventions: Ciclesonide; Drug
Lead sponsor: Covis Pharma S.à.r.l.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Eosinophilic Asthma
Interventions: ICS-LABA, benralizumab, Placebo for Benralizumab; Combination Product
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 34
States / cities: Chandler, Arizona • Sun City, Arizona • Tucson, Arizona + 28 more

Conditions: Rib Fractures
Interventions: Cryoablation, ESP Catheter; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Systemic Lupus Erythematosus
Interventions: Telitacicept, Placebo; Biological
Lead sponsor: Vor Biopharma; Industry
Eligibility: 12 Years to 70 Years
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 12
States / cities: Anniston, Alabama • Mission Hills, California • Orange, California + 9 more

Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Adult T-Cell Leukemia/Lymphoma, Aplastic Anemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, BCR-ABL1 Positive, Chronic Myelomonocytic Leukemia, Essential Thrombocythemia, Hematopoietic and Lymphatic System Neoplasm, Hodgkin Lymphoma, Multiple Myeloma, Myelodysplastic Syndrome, Myelofibrosis, Myeloid Neoplasm, Non-Hodgkin Lymphoma, Polycythemia Vera, Small Lymphocytic Lymphoma
Interventions: Fludarabine, Total-Body Irradiation, Donor Lymphocyte Infusion, Cyclophosphamide, Tacrolimus, Mycophenolate Mofetil, Hematopoietic Cell Transplantation, Melphalan, Bone Marrow Aspiration and Biopsy, Diagnostic Imaging, Biospecimen Collection; Drug · Radiation · Procedure
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2032
U.S. locations: 1
States / cities: Philadephia, Pennsylvania

Conditions: Photoallergy
Interventions: SPF 50 Y65 110 (BAY987519), SPF 50 Y51 002 (BAY987519), SPF 15 V27 104 (BAY987519), Sodium chloride [NaCl]; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Pinellas Park, Florida

Conditions: Diabetes Mellitus, Type 2
Interventions: Insulin Peglispro, Insulin Glargine, Insulin Lispro; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Aging
Interventions: Acute Intermittent Hypoxia, Computerized Cognitive Training; Device · Behavioral
Lead sponsor: University of Florida; Other
Eligibility: 65 Years to 89 Years
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Task Performance
Interventions: articulating Enseal, Ligasure device; Device
Lead sponsor: University of Louisville; Other
Eligibility: 18 Years to 100 Years · Female only
Enrollment: 142 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 2
States / cities: Louisville, Kentucky

Conditions: BK Polyomavirus, Kidney Diseases
Interventions: FK778; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 21
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 15 more

Conditions: Symptomatic Contact Lens Wearers
Interventions: FID 114675A Multi-Purpose Disinfecting Solution (MPDS), renu fresh Multi-Purpose Solution (MPS), Contact lenses; Device
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 591 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Fecal Incontinence
Interventions: Rusch Nasopharyngeal Airway; Device
Lead sponsor: Christiana Care Health Services; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 2
States / cities: Newark, Delaware • Wilmington, Delaware

Search by objective public record fields.

Comparison of Nexavar/Placebo as Maintenance Therapy for Patients With Advanced Ovarian or Primary Peritoneal Cancer

HyaloFAST Trial for Repair of Articular Cartilage in the Knee

A Comprehensive Approach to Secondary HIV Prevention and Care Among Positives

Childhood Outcomes of Preterm Brain Abnormalities

A Statewide Trial to Compare Three Training Models for Implementing an Evidence-based Treatment (EBT)

An RCT of a Primary Care-Based PTSD Intervention: Clinician-Supported PTSD Coach

Comparison of a Bone Product to Bone Dust in Ossification of Small Calvarial Defects.

Safety of Endoscopic Resection of Large Colorectal Polyps: A Randomized Trial.

Single-Dose PK Study of GBT440 in Subjects With Renal Impairment

Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Safety and Efficacy of Empiric Levothyroxine (LT4) Dose Increase Versus Individualized LT4 Dose Increase in Hypothyroid Women During Pregnancy

Comparison of Dobutamine and Regadenoson Stress Cardiac Magnetic Resonance (MR)

Comparison Between Systemic Exposure to Ciclesonide Nasal Spray, Ciclesonide HFA Nasal Aerosol and Orally Inhaled Ciclesonide (BY9010/M1-422)

Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment

Cryo Rib Fracture Study

A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-1)

Two Step Haplo With Radiation Conditioning

To Test for Photo Allergy Reaction of Sunscreens

A Study To Compare the Effects of Insulin Peglispro and Glargine on Insulin Sensitivity and Meal Time Insulin Requirements in Type 2 Diabetics

Enhancing Cognition in Older Adults With Intermittent Hypoxia and Cognitive Training

Articulating Enseal Versus Ligasure Energy Devices

Study of FK778 in Renal Transplant Recipients With Untreated BK Nephropathy

Alcon Multi-Purpose Disinfecting Solution Versus Renu Fresh Multi-Purpose Solution in Symptomatic Contact Lens Wearers

Comparison of Rectal Trumpet and Standard Care